Skip to main content

Eculizumab (Solirismab)

Eculizumab is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

It inhibits the cleavage of C5 by the C5 convertase into C5a, a potent anaphylatoxin with prothrombotic and proinflammatory properties, and C5b, which then forms the terminal complement complex C5b-9 which also has prothrombotic and proinflammatory effects. Both C5a and C5b-9 cause the complement-mediated events that are characteristic of PNH and aHUS.

It is administered through intravenous infusion every 2 weeks.

In 2016, it sold €500 million in Europe.

Labs that test for drug level:

University of Tours